Obermatt
See Similar Stocks →

Aspen Pharmacare

JNB:APN · ZAE000066692
PharmaceuticalsLarge

360

22
EV / EBIT58
Price / Owner Earnings93
Owner Earnings Yield1
Dividend Yield72
Price/Sales67
EV / Gross Profit58
Price/Book89
Return on Capital37
Cash Return on Capital20
Return on Equity32
EBIT Margin31
Gross Profitability11
Accruals79
Owner Earnings Margin11
Sales growth10
Profit Growth72
Long-Term EPS Growth48
Reinvestment12
Price momentum72
Debt load39
Refinancing92
Debt Payback1
Liquidity26
Analyst ratings57
Opinion Changes50
Price Target Upside14
Market mood54
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Aspen Pharmacare doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Africa
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeJSE
Founded1985
Employees3,099
Websiteaspenpharma.com
ISINZAE000066692
Last UpdateApr 2, 2026
Indices
JSE All Shares (South Africa)
Themes
CardiovascularEndocrinologyOncologyHematologyPain ManagementNeurologyCentral Nervous SystemWomen's HealthHealth Care

Description

Aspen Pharmacare Holdings Limited engages in development, manufacturing and marketing a wide range of healthcare products. The company possesses a diversified portfolio across various therapeutic categories, primarily focusing on branded and generic…

Analysis

Middle-of-the-road

Aspen Pharmacare Holdings Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
71
2023202420252026

All-time high

88

Jan 2024

All-time low

26

Jul 2025

Average rank

64

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
77
82
78
Price/Earnings
68
97
93
81
Price/Book
89
89
91
91
Dividend Yield
72
90
80
76
Value (overall)
92
99
93
89

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Aspen Pharmacare with its peers
Laurus Labs
NSI:LAURUSLABS
28
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Dr. Reddy's
NSI:DRREDDY
29
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Mega Lifesciences
SET:MEGA
78
CountryThailand
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Kalbe Farma
JKT:KLBF
85
CountryIndonesia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →